SAN DIEGO, July  27, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (&#34;Capricor&#34; or the &#34;Company&#34;) (NASDAQ:CAPR) or certain of its officers and

CAPR

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Capricor faces legal probe and FDA data questions after Reuters report

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Monday....

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, July  27, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (&amp;#34;Capricor&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:CAPR) or certain of its officers and</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Capricor Therapeutics faces a securities-law investigation by Johnson Fistel amid Reuters detailing FDA concerns over deramiocel data and trial design. The disclosure triggered a roughly 70% intraday stock drop on July 27, 2026, underscoring heightened regulatory and litigation risk surrounding Capricor&#039;s lead therapy. Near-term volatility may persist until clarity emerges from FDA discussions and any potential settlements.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel investigating Capricor for potential securities-law violations, misrepresentation or late disclosure.</li><li>Reuters reported FDA staff concerns on deramiocel efficacy data and measurement changes.</li><li>Capricor altered how primary results were measured (percentage vs 42-point test).</li><li>FDA reviewers questioned trial population cardiomyopathy relation due to normal baseline function.</li><li>Capricor stock plunged ~70% in early trading on July 27, 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Capricor Therapeutics, Inc. (CAPR)</strong>: Under investigation for potential securities-law violations; data concerns around deramiocel.</li><li><strong>Johnson Fistel, PLLP (N/A)</strong>: Promotional investor-law firm leading the inquiry; no direct market exposure.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on securities-law investigation and regulatory data concerns affecting Capricor&#039;s lead program, aligning with legal and corporate governance risk factors.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CAPR shares tumbled about 70% in intraday trading after Reuters report.</li><li>FDA advisers will discuss deramiocel’s effectiveness and risk-benefit profile.</li><li>Legal investigation may pressure Capricor’s valuation and cash-flow outlook.</li><li>Additional negative data or litigation could extend the downside.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of catalyst: July 27, 2026.</li><li>FDA staff concerns about deramiocel efficacy data reported by Reuters.</li><li>Capricor changed principal measurement from a 42-point test to percentage change.</li><li>FDA reviewers questioned whether trial population had Duchenne-related cardiomyopathy given normal baseline function.</li><li>Capricor stock declined approximately 70% in early trading on July 27, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CAPR likely remains volatile and biased to downside in the near term amid legal and regulatory scrutiny; watch FDA advisory outcomes and any settlements for direction.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, July  27, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CAPR">CAPR</a>) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.</p>  <p><strong>What if I purchased Capricor securities?</strong><br></br>If you purchased Capricor securities and suffered losses on your investment, you may join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=X-37xALf8hVp7dKraAPcjmjbmpPmCzrwPaMlu2Au3UFKzbuUN4BY6wHpq41ZqZS-Hq0mgLRtZtCYYVhpryovcETBT22aiHXWhMEJbfXecJxVsvXX2p520U3HxMyihA3mZd8oRp33zMVQw4v-jWkjY91D0QzsA_lMORt8MkJm7B7ESvo-UR9tCLdMwNCsVjW1" rel="nofollow" target="_blank">Click Here to Join the Investigation</a>.</p>  <p>Or for more information, contact James Baker at <a href="https://www.globenewswire.com/Tracker?data=msjPF7mkfL44kbhRKnNxpB6bzZ_W0rcZoYQMFqWzVKrvAcj38SY5ScdOUX9h8JqF1DScWaF5zU7_Sq-vZoEzonnRXAeHz4iOCvh2Nl8WJhE=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>What is Johnson Fistel Investigating?</strong><br></br>On July 27, 2026, Reuters reported that U.S. Food and Drug Administration staff reviewers raised concerns regarding the effectiveness data supporting deramiocel, Capricor’s experimental cell therapy for a heart condition associated with Duchenne muscular dystrophy. According to Reuters, the FDA briefing documents were released ahead of a meeting at which the agency’s external advisers are scheduled to discuss deramiocel’s effectiveness and risk-benefit profile.</p>  <p>Reuters reported that FDA staff stated that Capricor changed how it measured the principal results after the therapy’s late-stage trial ended. According to the report, Capricor calculated arm-function performance as a percentage change rather than analyzing scores using the originally planned 42-point test.</p>  <p>According to Reuters, FDA staff did not consider the conversion from raw change to percentage change and then back to raw change scientifically justified, stating that the approach added complexity and reduced accuracy.</p>  <p>Reuters further reported that FDA reviewers questioned whether the trial population had cardiomyopathy related to Duchenne muscular dystrophy because patients had normal heart-pumping function on average at the beginning of the trial.</p>  <p>Following this news, Capricor’s stock price declined approximately 70% in early trading on July 27, 2026, resulting in significant losses for investors.</p>  <p>Investors who purchased Capricor securities and suffered losses are encouraged to contact Johnson Fistel to discuss their rights and potential recovery options. There is no cost or obligation to participate.</p>  <p><strong>About Johnson Fistel, PLLP</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit <a href="https://www.globenewswire.com/Tracker?data=NUznnNm4OMTtIiw65zaGUn4dsES6ubZwHLsbf12t1ej61jkb26uP6U0FJ9Jg51x0_qNAzVu0CeB_Xg-78tv_zuaIEVmsjnwXEzyg0zpxX0Q=" rel="nofollow" target="_blank"><strong>www.johnsonfistel.com</strong></a>.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.</p>  <p>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact:</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800, San Diego, CA 92101<br></br>James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471<br></br><a href="https://www.globenewswire.com/Tracker?data=msjPF7mkfL44kbhRKnNxpB6bzZ_W0rcZoYQMFqWzVKp1EmdquxDVlADLp7iz-QlvUS299UDXdntpw92J6IPKQhhLfvNAxdBThFaYKeSqeNryvQ2p-UCB_zrB-1QZtdr59QBCBaApMP6Q__A5iGsLvUHSURFFvmexi6n6_v1aqKm0JRum7Go-B_9aPuiTvpMYmwShjsJ2DglgmL9PqqOoZ3KXfU326dHcYkYYPkC92tPkX-zhK94NflZ7oNpuZ2r3d_PufalTsl6vOfeP55_4Kg==" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or <a href="https://www.globenewswire.com/Tracker?data=o_Q39fUXOgnuc32H8KzabO7l2itGxsE7h-2LwRo940s8utYuuQGQQn_YccBu0ULeoLMer_V8d9Ikx6mAXi-lC2siza58VOE3Oby-B0XpSvI6LXedtqH2XS31ycF5PkBnfa0XVO7FNHzGdfIAmdoNtp1jIIZ6N-7ZlbTsRCgPcMgFCkOdapelkkzB9G8ZMQ_oAXWVvIb6TNR-yXfC5ORuXisKVX1_qLgmky28QbAmwgkOqWdBbmcmCiG-sYkrlMm12dJnuskYF4gc8IwMUVazjabQVj6Ed62F2dDpUFCP68alfJzD6lGGQQanu9KLh7fF" rel="nofollow" target="_blank">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc5ODY2OCM3NzQ0NzMyIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/N2M5NDAwOGQtZTMxMi00ZTRkLWJiYzMtNzcwY2U2ZGE2MTU2LTExOTMzNTgtMjAyNi0wNy0yNy1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Capricor Therapeutics faces a securities-law investigation by Johnson Fistel amid Reuters detailing FDA concerns over deramiocel data and trial design. The disclosure triggered a roughly 70% intraday stock drop on July 27, 2026, underscoring heightened regulatory and litigation risk surrounding Capricor's lead therapy. Near-term volatility may persist until clarity emerges from FDA discussions and any potential settlements.

News insight

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

AI summary

Sentiment rationale

Key facts

Legal